The effect of metformin on the risk of recurrent nonmelanoma skin cancers
Int J Dermatol
.
2020 Aug;59(8):e303-e305.
doi: 10.1111/ijd.14829.
Epub 2020 Mar 11.
Authors
Adarsh Ravishankar
1
,
Tianshun Zhang
2
,
Bruce R Lindgren
3
,
Ronda S Farah
4
,
Zigang Dong
2
,
Noah I Goldfarb
5
6
Affiliations
1
University of Minnesota Medical School, Minneapolis, MN, USA.
2
The Hormel Institute, University of Minnesota, Austin, MN, USA.
3
Masonic Cancer Center, University of Minnesota Biostatistics Core, Minneapolis, MN, USA.
4
Department of Dermatology, University of Minnesota, Minneapolis, MN, USA.
5
Departments of Medicine and Dermatology, University of Minnesota, Minneapolis, MN, USA.
6
Departments of Medicine and Dermatology, Minneapolis VA Medical Center, Minneapolis, MN, USA.
PMID:
32162316
PMCID:
PMC7673232
DOI:
10.1111/ijd.14829
No abstract available
Publication types
Letter
MeSH terms
Carcinoma, Basal Cell* / drug therapy
Humans
Metformin* / therapeutic use
Neoplasm Recurrence, Local
Skin Neoplasms* / drug therapy
Substances
Metformin
Grants and funding
UL1 TR002494/TR/NCATS NIH HHS/United States